home / stock / fblg / fblg news

FBLG News and Press, FibroBiologics Inc.

Stock Information
Company Name: FibroBiologics Inc.
Stock Symbol: FBLG
Market: NASDAQ
Website: fibrobiologics.com
Menu
FBLG FBLG Quote FBLG Short FBLG News FBLG Articles FBLG Message Board
Get FBLG Alerts

News, Short Squeeze, Breakout and More Instantly...
FBLG - FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...
FBLG - Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them PR Newswire Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC , March 3, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy market is projected to surpas...

FBLG - FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chro...

FBLG - FibroBiologics to Present at the BIO Investment & Growth Summit

HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - Expected earnings - FibroBiologics Inc.

FibroBiologics Inc. (FBLG) is expected to report $-0.09 for Q4 2025

FBLG - FibroBiologics reports FY results

2026-02-24 16:41:01 ET More on FibroBiologics FibroBiologics granted extension by Nasdaq to regain compliance FibroBiologics announces $1.7M registered direct offering Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBio...

FBLG - FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed payments of outstanding debt HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics...
FBLG - FibroBiologics granted extension by Nasdaq to regain compliance

2026-02-23 08:49:35 ET More on FibroBiologics FibroBiologics announces $1.7M registered direct offering FibroBiologics announces payoff of outstanding debt Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBiologics ...

FBLG - FibroBiologics Granted Extension by Nasdaq to Regain Compliance

HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...

FBLG - FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...
Next 10